Equity Long-Short Analyst

Pyari Menon

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cvrx-inc" target="_blank" data-smartkarma-citation="entities:37498:1" rel="noopener">CVRx (CVRX US)</a> stock was up 28% (including after hours) post 3Q2024 results commentary</li>
<li>Reassignment to MS-DRG 276, Category I CPT Code Approval and BeAT-HF trial milestones suggest solid long term outlook.</li>
<li>CVRx’s unique Barostim technology and the rising demand for heart failure treatments driven by aging demographics and lifestyle-related cardiac issues make it a compelling acquisition target.</li>
</ul>



CVRx (CVRX US) stock was up 28% (including after hours) post 3Q2024 results commentary
Reassignment to MS-DRG 276, Category I CPT Code Approval and BeAT-HF trial milestones suggest solid long term outlook.
CVRx’s unique Barostim technology and the rising demand for heart failure treatments driven by aging demographics and lifestyle-related cardiac issues make it a compelling acquisition target.


CVRX: Saying It Again and Again, Barostim Is Great Technology with a Bright Future

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cvrx-inc" target="_blank" data-smartkarma-citation="entities:37498:1" rel="noopener">CVRx (CVRX US)</a> was up 19% (including after hours) as the AMA accepted CPT Category I codes for Barostim. Codes are to be implemented on January 1, 2026</li>
<li>With Category I CPT codes CVRX should see the benefits of clinical validation, regulatory de-risking, reimbursement potential, increased market access and significant improvement in revenue potential</li>
<li>Barostim is the only neuromodulation device for heart failure and resistant hypertension, positioning CVRx as a compelling acquisition target due to its unique technology and strong market potential.</li>
</ul>



CVRx (CVRX US) was up 19% (including after hours) as the AMA accepted CPT Category I codes for Barostim. Codes are to be implemented on January 1, 2026
With Category I CPT codes CVRX should see the benefits of clinical validation, regulatory de-risking, reimbursement potential, increased market access and significant improvement in revenue potential
Barostim is the only neuromodulation device for heart failure and resistant hypertension, positioning CVRx as a compelling acquisition target due to its unique technology and strong market potential.


CVRX: Great Technology that Now Has a Bright Future

<ul>
<li>
<strong><a href="https://www.smartkarma.com/entities/cvrx-inc" target="_blank" data-smartkarma-citation="entities:37498:1" rel="noopener">CVRx (CVRX US)'s</a></strong> Barostim, is the only neuromodulation device designed to treat heart failure and resistant hypertension. We see CVRX as a buyout target. </li>
<li>Growth will be driven by growing elderly population, and rising rates of diabetes and hypertension putting more people in cardiac decline.</li>
<li>Trials suggest that Barostim is a cost-effective treatment, quality of life improving therapy when compared with traditional optimal medical management in patients with resistant hypertension.</li>
</ul>



CVRx (CVRX US)'s Barostim, is the only neuromodulation device designed to treat heart failure and resistant hypertension. We see CVRX as a buyout target. 
Growth will be driven by growing elderly population, and rising rates of diabetes and hypertension putting more people in cardiac decline.
Trials suggest that Barostim is a cost-effective treatment, quality of life improving therapy when compared with traditional optimal medical management in patients with resistant hypertension.


CVRx: Enhancing Cardiac Care Through Neuromodulation

United States

CVRx, Inc. develops and manufactures medical devices. The Company specializes in technology for an implantable device for the treatment of hypertension and heart failure that triggers the body's master blood flow regulation system. CVRx serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CVRx (CVRX US)

CVRX: Saying It Again and Again, Barostim Is Great Technology with a Bright Future

CVRx's Barostim now benefits from enhanced reimbursement code approvals, which will drive higher adoption rates. Clinical trials show improved...

Pyari Menon

CVRX: Great Technology that Now Has a Bright Future

Barostim's strong clinical validation, and new CPT codes will boost reimbursement potential and makes CVRX a strategic buyout target for larger...

Pyari Menon

CVRx: Enhancing Cardiac Care Through Neuromodulation

One of a kind innovative Barostim technology, strong clinical results, and robust growth potential in cardiovascular care.

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)